Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 7/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | CTSB | P07858 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | CASP6 | P55212 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31481292 | 1.00 | GPR35 (0.44) | GPR35ALDH1A1TDP1MCL1MEN1 | |
| SCHEMBL31571463 | 0.80 | GPR35 (0.47) | GPR35ALDH1A1TDP1MCL1MEN1 | |
| SCHEMBL1191637 | 0.80 | GPR35 (0.47) | GPR35ALDH1A1TDP1MCL1MEN1 | |
| SCHEMBL843559 | 0.80 | ALDH1A1 (0.54) | ALDH1A1TDP1MEN1KMT2AMAPT | |
| SCHEMBL30197316 | 0.80 | ALDH1A1 (0.54) | ALDH1A1TDP1MEN1KMT2AMAPT | |
| Ammonia Solution, Strong SCHEMBL27851817 | 0.78 | ALDH1A1 (0.52) | ALDH1A1TDP1MEN1KMT2AMAPT | |
| SCHEMBL2747917 | 0.78 | TSHR (0.45) | ALDH1A1TDP1MEN1KMT2AMAPT | |
| SCHEMBL2747912 | 0.78 | TSHR (0.45) | ALDH1A1TDP1MEN1KMT2AMAPT | |
| SCHEMBL2972185 | 0.77 | ALDH1A1 (0.44) | ALDH1A1TDP1MEN1KMT2AMAPT | |
| SCHEMBL5126783 | 0.77 | PKM (0.42) | ALDH1A1TDP1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116410125-A | Preparation method of 2-methyl-3-nitro-4-hydroxypyridine | 嘉兴逸泰生物科技有限公司 | 2023-07-11 | — | — | CN | claimed |
| US-20250145601-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | SATYA THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| EP-4482831-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | Satya Therapeutics, Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| CN-118696034-A | Novel bicyclic compounds as RAD51 inhibitors | 萨提亚疗法股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| WO-2023161782-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | SATYARX PHARMA INNOVATIONS PVT LTD (IN) | 2023-08-31 | — | — | WO | disclosed |
| CN-116410125-A | Preparation method of 2-methyl-3-nitro-4-hydroxypyridine | 嘉兴逸泰生物科技有限公司 | 2023-07-11 | — | — | CN | disclosed |
| CN-116410125-A | Preparation method of 2-methyl-3-nitro-4-hydroxypyridine | 嘉兴逸泰生物科技有限公司 | 2023-07-11 | — | — | CN | disclosed |
| CN-116410125-A | Preparation method of 2-methyl-3-nitro-4-hydroxypyridine | 嘉兴逸泰生物科技有限公司 | 2023-07-11 | — | — | CN | disclosed |
| US-20190194179-A1 | ANTIBIOTIC COMPOUNDS | DISCUVA LTD. (GB) | 2019-06-27 | — | — | US | disclosed |
| EP-3500567-A1 | ANTIBIOTIC COMPOUNDS | Discuva Ltd. (GB) | 2019-06-26 | — | — | EP | disclosed |
| US-5753641-A | SYNERGISTIC THERAPY COMPRISING FINASTERIDE AND TERAZOSIN DRUGS | MERCK & CO., INC. (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0750620-A4 | CARBAPENEM COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT | MERCK & CO INC (US) | 1997-07-16 | — | — | EP | disclosed |
| EP-0750620-A1 | CARBAPENEM COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT | MERCK & CO. INC. (US) | 1997-01-02 | — | — | EP | disclosed |
| US-5496816-A | Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment | MERCK & CO., INC. (US) | 1996-03-05 | — | — | US | disclosed |
| WO-1995025108-A1 | CARBAPENEM COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 1995-09-21 | — | — | WO | disclosed |
| EP-0576603-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC HYPERPLASIA, CONTAINING A 5 ALPHA-REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO. INC. (US) | 1994-01-05 | — | — | EP | disclosed |
| EP-0526093-A1 | New non-steroidal agents as 5-alpha reductase inhibitors | MERCK & CO. INC. (US) | 1993-02-03 | — | — | EP | disclosed |
| WO-1992018132-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA COMTAINING A 5 ALPHA-REDUCTASE INHIBITOR | MERCK & CO., INC. (US) | 1992-10-29 | — | — | WO | disclosed |
| WO-1992016213-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC HYPERPLASIA, CONTAINING A 5 ALPHA-REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
| WO-1992016233-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC CANCER CONTAINING A 5 ALPHA REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194179-A1 | ANTIBIOTIC COMPOUNDS | B3GNT2, RPN2, RPN1 | GPR35 1158/4885ALDH1A1 3333/4885TDP1 3374/4885 |
| US-20250145601-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | RAD51, ERCC4, ERCC2 | GPR35 4077/4885ALDH1A1 4307/4885TDP1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.